• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form S-8 filed by Annovis Bio Inc.

    6/21/24 5:15:56 PM ET
    $ANVS
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $ANVS alert in real time by email
    S-8 1 tm2417417d1_s8.htm S-8

     

    As filed with the Securities and Exchange Commission on June 21, 2024 

    Registration No. 333-            

     

     

    UNITED STATES 

    SECURITIES AND EXCHANGE COMMISSION 

    Washington, D.C. 20549

     

    FORM S-8 

    REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933

     

    ANNOVIS BIO, INC. 

    (Exact name of registrant as specified in its charter)

     

    Delaware     26-2540421
    (State or other jurisdiction of
    incorporation or organization)
        (I.R.S. Employer
    Identification Number)
           
    101 Lindenwood Drive, Suite 225
    Malvern, PA 19355
    (Address of principal executive offices, Zip Code)

     

    Annovis Bio, Inc. Amended and Restated 2019 Equity Incentive Plan 

    (Full title of the plan)

     

    Maria Maccecchini, Ph.D.
    President and Chief Executive Officer
    Annovis Bio, Inc.
    101 Lindenwood Drive, Suite 225
    Malvern, PA 19355
     

    (Name and address of agent for service)

     

    (484) 875-3192 

    (Telephone number, including area code, of agent for service)

     

    Copies to:

     

    Mitchell S. Nussbaum, Esq.

    Janeanne Ferrari, Esq.

    Loeb & Loeb LLP

    345 Park Avenue

    New York, NY 10154

    (212) 407-4000

    Joan Guilfoyle, Esq.
    Loeb & Loeb LLP
    901 New York Avenue NW
    Suite 300 East

    Washington, DC 20001
    (202) 618-5000

     

     

    Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth company. See definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

     

    Large accelerated filer ¨   Accelerated filer ¨  
               
    Non-accelerated filer  x   Smaller reporting company x  
               
          Emerging growth company      x  

     

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided to Section 7(a)(2)(B) of the Securities Act. ¨

     

     

     

     

     

    EXPLANATORY NOTE

     

    This Registration Statement is being filed by Annovis Bio, Inc. (the “Company”) pursuant to General Instruction E of Form S-8 under the Securities Act to register an additional 1,000,000 shares of the Company’s common stock, par value $0.0001 per share (the “Common Stock”), for issuance in connection with awards under the pursuant to the Amended and Restated 2019 Equity Incentive Plan (the “Amended Plan”). The Amended Plan was approved by the Company’s stockholders on June 12, 2024. The Amendment increases the number of shares of Common Stock authorized for issuance under the Amended Plan from 2,000,000 shares to 3,000,000 shares (an increase of 1,000,000 shares).

     

    Except as set forth below, the contents of the Company’s registration statement on Form S-8 (File No. 333-236457) filed with the U.S. Securities and Exchange Commission (the “SEC”) on February 14, 2020 and relating to shares of Common Stock issuable in connection with awards under the 2019 Plan prior to the Amendment are incorporated by reference herein as permitted by General Instruction E of Form S-8.

     

    PART I

     

    INFORMATION REQUIRED IN THE SECTION 10(a) PROSPECTUS

     

    The information specified in Item 1 and Item 2 of Part I of Form S-8 is omitted from this Registration Statement on Form S-8 (the “Registration Statement”) in accordance with the provisions of Rule 428 under the Securities Act of 1933, as amended (the “Securities Act”), and the introductory note to Part I of Form S-8. The documents containing the information specified in Part I of Form S-8 will be delivered to the participants in the respective plans. Such documents are not required to be, and are not, filed with the Securities and Exchange Commission (the “Commission”) either as part of this Registration Statement or as a prospectus or prospectus supplement pursuant to Rule 424 under the Securities Act.

     

    PART II

     

    INFORMATION REQUIRED IN THE REGISTRATION STATEMENT

     

    Item 3. Incorporation of Documents by Reference.

     

    The following documents filed with the Commission pursuant to the Securities Exchange Act of 1934, as amended (the “Exchange Act”), are incorporated into this Registration Statement by reference:

     

    (a)      The Registrant’s Annual Report on Form 10-K for the fiscal year ended December 31, 2023 as filed with the Securities and Exchange Commission on March 29, 2024;

     

    (b)      All other reports filed pursuant to Section 13(a) or 15(d) of the Exchange Act since December 31, 2023; and

     

    (c)       The description of the Registrant’s Common Stock contained in the Company’s Registration Statement on Form 8-A (File No. 001-39202) filed with the Commission on November 17, 2021, pursuant to Section 12(b) of the Exchange Act, including any amendment or report filed for the purpose of updating such description.

     

    In addition, all documents filed by the Registrant pursuant to Sections 13(a), 13(c), 14 or 15(d) of the Exchange Act after the date hereof, but prior to the filing of a post-effective amendment to this Registration Statement that indicates that all securities offered hereby have been sold or that deregisters all such securities then remaining unsold, shall be deemed to be incorporated by reference in this Registration Statement and to be a part hereof from the date of filing of such documents. Notwithstanding the foregoing, unless specifically stated to the contrary in such filing, none of the information that the Registrant discloses under Items 2.02 or 7.01 of any Current Report on Form 8-K that it may from time to time furnish to the Commission will be incorporated by reference into, or otherwise be included in or deemed to be a part of, this Registration Statement.

     

    For purposes of this Registration Statement, any document or any statement contained in a document incorporated or deemed to be incorporated herein by reference shall be deemed to be modified or superseded to the extent that a subsequently filed document or a statement contained herein or in any other subsequently filed document that also is or is deemed to be incorporated herein by reference modifies or supersedes such document or such statement in such document. Any statement so modified or superseded shall not be deemed, except as so modified or superseded, to constitute a part of this Registration Statement. Subject to the foregoing, all information in this Registration Statement is so qualified in its entirety by the information appearing in the documents incorporated herein by reference.

     

    Item 4. Description of Securities.

     

    Not applicable.

     

    Item 5. Interests of Named Experts and Counsel.

     

    Not applicable.

     

     

     

     

    Item 6. Indemnification of Directors and Officers.

     

    Section 102 of the General Corporation Law of the State of Delaware permits a corporation to eliminate the personal liability of directors of a corporation to the corporation or its stockholders for monetary damages for a breach of fiduciary duty as a director, except where the director breached his or her duty of loyalty, failed to act in good faith, engaged in intentional misconduct or knowingly violated a law, authorized the payment of a dividend or approved a stock repurchase in violation of Delaware corporate law or obtained an improper personal benefit. Our restated certificate of incorporation provides that no director of the Registrant shall be personally liable to it or its stockholders for monetary damages for any breach of fiduciary duty as a director, notwithstanding any provision of law imposing such liability, except to the extent that the General Corporation Law of the State of Delaware prohibits the elimination or limitation of liability of directors for breaches of fiduciary duty.

     

    Section 145 of the General Corporation Law of the State of Delaware provides that a corporation has the power to indemnify a director, officer, employee, or agent of the corporation, or a person serving at the request of the corporation for another corporation, partnership, joint venture, trust or other enterprise in related capacities against expenses (including attorneys' fees), judgments, fines and amounts paid in settlement actually and reasonably incurred by the person in connection with an action, suit or proceeding to which he or she was or is a party or is threatened to be made a party to any threatened, ending or completed action, suit or proceeding by reason of such position, if such person acted in good faith and in a manner he or she reasonably believed to be in or not opposed to the best interests of the corporation, and, in any criminal action or proceeding, had no reasonable cause to believe his or her conduct was unlawful, except that, in the case of actions brought by or in the right of the corporation, no indemnification shall be made with respect to any claim, issue or matter as to which such person shall have been adjudged to be liable to the corporation unless and only to the extent that the Court of Chancery or other adjudicating court determines that, despite the adjudication of liability but in view of all of the circumstances of the case, such person is fairly and reasonably entitled to indemnity for such expenses which the Court of Chancery or such other court shall deem proper.

     

     

     

     

    Our restated certificate of incorporation provides that we will indemnify each person who was or is a party or threatened to be made a party to any threatened, pending or completed action, suit or proceeding (other than an action by or in the right of us) by reason of the fact that he or she is or was, or has agreed to become, a director or officer, or is or was serving, or has agreed to serve, at our request as a director, officer, partner, employee or trustee of, or in a similar capacity with, another corporation, partnership, joint venture, trust or other enterprise (all such persons being referred to as an "Indemnitee"), or by reason of any action alleged to have been taken or omitted in such capacity, against all expenses (including attorneys' fees), judgments, fines and amounts paid in settlement actually and reasonably incurred in connection with such action, suit or proceeding and any appeal therefrom, if such Indemnitee acted in good faith and in a manner he or she reasonably believed to be in, or not opposed to, our best interests, and, with respect to any criminal action or proceeding, he or she had no reasonable cause to believe his or her conduct was unlawful. Our restated certificate of incorporation provides that we will indemnify any Indemnitee who was or is a party to an action or suit by or in the right of us to procure a judgment in our favor by reason of the fact that the Indemnitee is or was, or has agreed to become, a director or officer, or is or was serving, or has agreed to serve, at our request as a director, officer, partner, employee or trustee of, or in a similar capacity with, another corporation, partnership, joint venture, trust or other enterprise, or by reason of any action alleged to have been taken or omitted in such capacity, against all expenses (including attorneys' fees) and, to the extent permitted by law, amounts paid in settlement actually and reasonably incurred in connection with such action, suit or proceeding, and any appeal therefrom, if the Indemnitee acted in good faith and in a manner he or she reasonably believed to be in, or not opposed to, our best interests, except that no indemnification shall be made with respect to any claim, issue or matter as to which such person shall have been adjudged to be liable to us, unless a court determines that, despite such adjudication but in view of all of the circumstances, he or she is entitled to indemnification of such expenses. Notwithstanding the foregoing, to the extent that any Indemnitee has been successful, on the merits or otherwise, he or she will be indemnified by us against all expenses (including attorneys' fees) actually and reasonably incurred in connection therewith. Expenses must be advanced to an Indemnitee under certain circumstances.

     

    We have entered into indemnification agreements with each of our directors and officers. These indemnification agreements may require us, among other things, to indemnify our directors and officers for some expenses, including attorneys' fees, judgments, fines and settlement amounts incurred by a director or officer in any action or proceeding arising out of his or her service as one of our directors or officers, or any of our subsidiaries or any other company or enterprise to which the person provides services at our request.

     

    We maintain a general liability insurance policy that covers certain liabilities of directors and officers of our corporation arising out of claims based on acts or omissions in their capacities as directors or officers.

     

     

     

     

    Item 7. Exemption from Registration Claimed.

     

    Not applicable.

     

    Item 8. Exhibits.

     

    The following Exhibits are filed as part of this Registration Statement:

     

    Exhibit 
    No.
      Description
    4.1   Amended and Restated Certificate of Incorporation of the Registrant. (Incorporated by reference to Exhibit 3.1 to the Current Report filed February 6, 2020) as amended by Certificate of Amendment to Amended and Restated Certificate of Incorporation (incorporated by reference to Exhibit 3.1 to the Current Report on Form 8-K filed June 16, 2023.)
         
    4.2   Amended and Restated Bylaws of the Registrant. (Incorporated by reference to Exhibit 3.2 to the Current Report filed February 6, 2020)
         
    4.3   Annovis Bio, Inc. Amended and Restated 2019 Equity Incentive Plan. (incorporated by reference as Annex A to Definitive Proxy Statement on Schedule 14A filed April 29, 2024.)
         
    5.1*   Opinion of Loeb & Loeb LLP regarding the legality of the securities being registered

     

    23.1*   Consent of Ernst & Young LLP
         
    23.2*   Consent of WithumSmith+Brown,
         
    23.3*   Consent of Loeb & Loeb LLP (included in Exhibit 5.1)
         
    107*   Fee Rate Table

     

    * Filed herewith.

     

    Item 9. Undertakings.

     

    (a)       The undersigned Registrant hereby undertakes:

     

    (1)        To file, during any period in which offers or sales are being made, a post-effective amendment to this Registration Statement:

     

    (i)    To include any prospectus required by Section 10(a)(3) of the Securities Act;

     

    (ii)   To reflect in the prospectus any facts or events arising after the effective date of the Registration Statement (or the most recent post-effective amendment thereof) which, individually or in the aggregate, represent a fundamental change in the information set forth in the Registration Statement. Notwithstanding the foregoing, any increase or decrease in volume of securities offered (if the total dollar value of securities offered would not exceed that which was registered) and any deviation from the low or high end of the estimated maximum offering range may be reflected in the form of prospectus filed with the Commission pursuant to Rule 424(b) if, in the aggregate, the changes in volume and price represent no more than a 20% change in the maximum aggregate offering price set forth in the “Calculation of Registration Fee” table in the effective Registration Statement;

     

    (iii) To include any material information with respect to the plan of distribution not previously disclosed in the Registration Statement or any material change to such information in the Registration Statement.

     

    provided, however, that paragraphs (a)(1)(i) and (a)(1)(ii) do not apply if the information required to be included in a post-effective amendment by those paragraphs is contained in reports filed with or furnished to the Commission by the Registrant pursuant to Section 13 or Section 15(d) of the Exchange Act that are incorporated by reference in the Registration Statement.

     

    (2)        That, for the purpose of determining any liability under the Securities Act, each such post-effective amendment shall be deemed to be a new Registration Statement relating to the securities offered therein, and the offering of such securities at that time shall be deemed to be the initial bona fide offering thereof.

     

     

     

     

    (3)         To remove from registration by means of a post-effective amendment any of the securities being registered which remain unsold at the termination of the offering.

     

    (b)      The undersigned Registrant hereby undertakes that, for purposes of determining any liability under the Securities Act, each filing of the Registrant’s annual report pursuant to Section 13(a) or Section 15(d) of the Exchange Act (and, where applicable, each filing of an employee benefit plan’s annual report pursuant to Section 15(d) of the Exchange Act)  that is incorporated by reference in the Registration Statement shall be deemed to be a new Registration Statement relating to the securities offered therein, and the offering of such securities at that time shall be deemed to be the initial bona fide offering thereof.

     

    (c)       Insofar as indemnification for liabilities arising under the Securities Act may be permitted to directors, officers and controlling persons of the Registrant pursuant to the foregoing provisions, or otherwise, the Registrant has been advised that in the opinion of the Commission such indemnification is against public policy as expressed in the Securities Act and is, therefore, unenforceable. In the event that a claim for indemnification against such liabilities (other than the payment by the Registrant of expenses incurred or paid by a director, officer or controlling person of the registrant in the successful defense of any action, suit or proceeding) is asserted by such director, officer or controlling person in connection with the securities being registered, the registrant will, unless in the opinion of its counsel the matter has been settled by controlling precedent, submit to a court of appropriate jurisdiction the question whether such indemnification by it is against public policy as expressed in the Securities Act and will be governed by the final adjudication of such issue.

     

     

     

     

    SIGNATURES

     

    Pursuant to the requirements of the Securities Act of 1933, the Registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form S-8 and has duly caused this Registration Statement to be signed on its behalf by the undersigned, thereunto duly authorized, in the Borough of Malvern, Commonwealth of Pennsylvania, on June 21, 2024.

     

      ANNOVIS BIO, INC.
       
      By: /s/ Maria Maccecchini
        Name: Maria Maccecchini
        Title: Chief Executive Officer

     

    Pursuant to the requirements of the Securities Act of 1933, this Registration Statement has been signed by the following persons in the capacities and on the date indicated.

     

    Signature   Title   Date
             
    /s/ Maria Maccecchini   President and Chief Executive Officer   June 21, 2024
    Maria Maccecchini   (Principal Executive Officer & Interim Principal Financial Officer)    
             
    /s/ Michael Hoffman   Chairman of the Board and Director   June 21, 2024
    Michael Hoffman        
             
    /s/ Claudine Bruck   Director   June 21, 2024
    Claudine Bruck        
             
    /s/ Reid McCarthy   Director   June 21, 2024
    Reid McCarthy        
             
    /s/ Mark White   Director   June 21, 2024
    Mark White        

     

     

     

    Get the next $ANVS alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $ANVS

    DatePrice TargetRatingAnalyst
    2/10/2025Buy → Hold
    D. Boral Capital
    10/25/2024$25.00Hold → Buy
    Maxim Group
    12/29/2023$36.00Buy
    Canaccord Genuity
    7/7/2021$45.00 → $150.00Buy
    Maxim Group
    More analyst ratings

    $ANVS
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Hoffman Michael B bought $193,794 worth of shares (45,000 units at $4.31), increasing direct ownership by 2% to 2,574,739 units (SEC Form 4)

    4 - Annovis Bio, Inc. (0001477845) (Issuer)

    12/8/25 8:05:14 PM ET
    $ANVS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: Director Hoffman Michael B bought $159,886 worth of shares (39,200 units at $4.08), increasing direct ownership by 2% to 2,529,739 units (SEC Form 4)

    4/A - Annovis Bio, Inc. (0001477845) (Issuer)

    11/25/25 6:59:54 PM ET
    $ANVS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Hoffman Michael B bought $159,886 worth of shares (39,200 units at $4.08), increasing direct ownership by 2% to 2,519,739 units (SEC Form 4)

    4 - Annovis Bio, Inc. (0001477845) (Issuer)

    11/25/25 12:26:46 PM ET
    $ANVS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ANVS
    SEC Filings

    View All

    Annovis Bio Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits

    8-K - Annovis Bio, Inc. (0001477845) (Filer)

    1/28/26 4:28:34 PM ET
    $ANVS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 10-Q filed by Annovis Bio Inc.

    10-Q - Annovis Bio, Inc. (0001477845) (Filer)

    11/12/25 4:16:53 PM ET
    $ANVS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Annovis Bio Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Other Events, Financial Statements and Exhibits

    8-K - Annovis Bio, Inc. (0001477845) (Filer)

    10/28/25 5:07:47 PM ET
    $ANVS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ANVS
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Annovis Announces Open-Label Extension Study for Parkinson's Disease Patients

    Enrollment will begin in January 2026 Participants will be treated with buntanetap for 36 months The study aims to enroll 500 patients MALVERN, Pa., Dec. 18, 2025 (GLOBE NEWSWIRE) -- Annovis Bio, Inc. (NYSE:ANVS) ("Annovis" or the "Company"), a late-stage clinical drug platform company pioneering transformative therapies for neurodegenerative diseases such as Alzheimer's disease (AD) and Parkinson's disease (PD), today announced it will begin an Open-Label Extension (OLE) study in January 2026 to evaluate the long-term safety and efficacy of buntanetap in PD patients. "Launching the OLE study is a natural next step for our Parkinson's program," said Maria Maccecchini, Ph.D., President

    12/18/25 4:35:00 PM ET
    $ANVS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Annovis to Host Corporate Update Webinar on January 28, 2026

    MALVERN, Pa., Dec. 16, 2025 (GLOBE NEWSWIRE) -- Annovis Bio, Inc. (NYSE:ANVS) ("Annovis" or the "Company"), a late-stage clinical drug platform company pioneering transformative therapies for neurodegenerative diseases such as Alzheimer's disease (AD) and Parkinson's disease (PD), today announced it will host a corporate update webinar followed by a live Q&A session. The webinar will feature Maria Maccecchini, Ph.D., President and CEO, who will provide an overview of the Company's recent progress, ongoing clinical programs, and strategic directions. Webinar details Date: Wednesday, January 28, 2026Time: 4:30 p.m. ETPresenter: Maria Maccecchini, Ph.D., President and CEORegistration link

    12/16/25 8:00:00 AM ET
    $ANVS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Annovis To Present at the 2025 Annual Meeting of the Parkinson Study Group

    MALVERN, Pa., Dec. 03, 2025 (GLOBE NEWSWIRE) -- Annovis Bio, Inc. (NYSE:ANVS) ("Annovis" or the "Company"), a late-stage clinical drug platform company pioneering transformative therapies for neurodegenerative diseases such as Alzheimer's disease (AD) and Parkinson's disease (PD), today announced it will present at the 2025 Annual Meeting of the Parkinson Study Group (PSG), taking place December 4-6, 2025 in San Diego, California. The presentation builds on momentum from the Company's recent Phase 3 PD biomarker data, showing that patients with amyloid co-pathology experience more pronounced cognitive decline, which is counteracted and reversed by buntanetap. In the same patients, buntane

    12/3/25 8:00:00 AM ET
    $ANVS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ANVS
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Hoffman Michael B bought $193,794 worth of shares (45,000 units at $4.31), increasing direct ownership by 2% to 2,574,739 units (SEC Form 4)

    4 - Annovis Bio, Inc. (0001477845) (Issuer)

    12/8/25 8:05:14 PM ET
    $ANVS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: Director Hoffman Michael B bought $159,886 worth of shares (39,200 units at $4.08), increasing direct ownership by 2% to 2,529,739 units (SEC Form 4)

    4/A - Annovis Bio, Inc. (0001477845) (Issuer)

    11/25/25 6:59:54 PM ET
    $ANVS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Hoffman Michael B bought $159,886 worth of shares (39,200 units at $4.08), increasing direct ownership by 2% to 2,519,739 units (SEC Form 4)

    4 - Annovis Bio, Inc. (0001477845) (Issuer)

    11/25/25 12:26:46 PM ET
    $ANVS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ANVS
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Annovis Bio downgraded by D. Boral Capital

    D. Boral Capital downgraded Annovis Bio from Buy to Hold

    2/10/25 8:18:59 AM ET
    $ANVS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Annovis Bio upgraded by Maxim Group with a new price target

    Maxim Group upgraded Annovis Bio from Hold to Buy and set a new price target of $25.00

    10/25/24 7:56:01 AM ET
    $ANVS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Canaccord Genuity initiated coverage on Annovis Bio with a new price target

    Canaccord Genuity initiated coverage of Annovis Bio with a rating of Buy and set a new price target of $36.00

    12/29/23 7:03:31 AM ET
    $ANVS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ANVS
    Leadership Updates

    Live Leadership Updates

    View All

    Annovis Provides Corporate Updates and Reports Third Quarter 2025 Financial Results

    MALVERN, Pa., Nov. 12, 2025 (GLOBE NEWSWIRE) -- Annovis Bio, Inc. (NYSE:ANVS) ("Annovis" or the "Company"), a late-stage clinical drug platform company pioneering transformative therapies for neurodegenerative diseases such as Alzheimer's disease (AD) and Parkinson's disease (PD), today provided corporate updates and third quarter 2025 financial results. "The past quarter delivered breakthrough progress on every front," said Maria Maccecchini, Ph.D., President and CEO of Annovis. "Our pivotal Phase 3 Alzheimer's study has achieved full activation across all clinical sites, with enrollment momentum advancing every day. We have fortified our intellectual property position by transferring al

    11/12/25 8:00:00 AM ET
    $ANVS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Annovis Appoints Mark Guerin as Chief Financial Officer

    MALVERN, Pa., Sept. 25, 2025 (GLOBE NEWSWIRE) -- Annovis Bio, Inc. (NYSE: ANVS) ("Annovis" or the "Company"), a late-stage clinical drug platform company pioneering transformative therapies for neurodegenerative diseases such as Alzheimer's disease (AD) and Parkinson's disease (PD), today announced the appointment of Mark Guerin, CPA, CMA, CFM, as Chief Financial Officer (CFO) to help lead the Company through a pivotal phase as buntanetap continues to show promise in late-stage clinical development. Mr. Guerin has extensive experience and a successful track record in managing financial operations within biopharma companies. In 2013, he joined Onconova Therapeutics, now known as Traws Phar

    9/25/25 7:30:00 AM ET
    $ANVS
    $TRAW
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Annovis Bio Appoints Hui Liu as Director of Biostatistics

    MALVERN, Pa., April 29, 2025 (GLOBE NEWSWIRE) -- Annovis Bio Inc. (NYSE:ANVS) ("Annovis" or the "Company"), a late-stage clinical drug platform company developing transformative therapies for neurodegenerative disorders such as Alzheimer's disease (AD) and Parkinson's disease (PD), today announced the appointment Hui Liu as Director of Biostatistics. "Bringing Ms. Liu on board at this critical stage, as our pivotal Phase 3 AD trial advances, reinforces our commitment to scientific excellence," said Cheng Fang, Ph.D., Senior Vice President, Research and Development. "Her statistical expertise will help ensure the integrity of our data and support robust regulatory submissions as we move to

    4/29/25 8:00:00 AM ET
    $ANVS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ANVS
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G/A filed by Annovis Bio Inc. (Amendment)

    SC 13G/A - Annovis Bio, Inc. (0001477845) (Subject)

    11/28/23 4:05:14 PM ET
    $ANVS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G filed by Annovis Bio Inc.

    SC 13G - Annovis Bio, Inc. (0001477845) (Subject)

    11/8/23 7:02:36 AM ET
    $ANVS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ANVS
    Financials

    Live finance-specific insights

    View All

    Annovis Bio Announces Positive Phase 2 Efficacy Data for the Treatment of Parkinson's Disease

    Data Shows Statistically Significant Improvements in Speed and Motor Function in PD PatientsAnnovis Bio to Request Meeting with FDA on Next Steps in Clinical DevelopmentInvestor Conference Call to be Hosted Tuesday, October 5th, 2021, at 9:00 am ETBerwyn, Pennsylvania--(Newsfile Corp. - October 5, 2021) - Annovis Bio, Inc. (NYSE:ANVS) ("Annovis" or the "Company"), a clinical-stage drug platform company addressing Alzheimer's disease (AD), Parkinson's disease (PD) and other neurodegenerative diseases, today announced results from the completed dose response Phase 2 clinical trial of ANVS401 in 54 PD patients, which found that once-daily ANVS401 was superior to placebo in improving motor funct

    10/5/21 8:00:00 AM ET
    $ANVS
    Biotechnology: Pharmaceutical Preparations
    Health Care